scPharmaceuticals (SCPH)
(Delayed Data from NSDQ)
$5.52 USD
+0.35 (6.77%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $5.52 0.00 (0.00%) 7:08 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
scPharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SCPH 5.52 +0.35(6.77%)
Will SCPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SCPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SCPH
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
SCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for SCPH
scPharmaceuticals Holds Annual Stockholders Meeting June 2025
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Craig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
scPharmaceuticals Earnings Call Highlights Growth and Expansion